Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer

EMJ has 458 videos Subscribe Here

Description: At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, explains the rationale and design of PlanB, a prospective phase 3 trial evaluating the Oncotype DX® 21-gene Recurrence Score® result for defining a low-risk subgroup of breast cancer patients with node-negative disease and high-risk clinicopathological factors as well as patients with node-positive disease who could be treated with adjuvant endocrine therapy alone.

This content is supported by Genomic Health, Inc.


European Medical Journal

Shared By : EMJ
Posted on : 06/02/16
Added : 3 years ago
Category : Breast Cancer